Fintel reports that on November 7, 2024, Argus Research downgraded their outlook for Palantir Technologies (NYSE:PLTR) from ...

Fintel reports that on November 4, 2024, Argus Research upgraded their outlook for AbbVie (NYSE:ABBV) from Hold to Buy.

In a report released on November 1, David Toung from Argus Research maintained a Buy rating on Stryker (SYK – Research Report). The ...

Fintel reports that on November 4, 2024, Argus Research upgraded their outlook for AbbVie (SNSE:ABBVCL) from Hold to Buy. There are 4,864 funds or institutions reporting positions in AbbVie.

Argus raised the firm’s price target on Wynn Resorts (WYNN) to $105 from $90 and keeps a Buy rating on the shares. The prospects for an ...

Fintel reports that on November 4, 2024, Argus Research upgraded their outlook for AbbVie (LSE:0QCV) from Hold to Buy. As of October 23, 2024, the average one-year price target for AbbVie is 205. ...

It is a sad reality that ratf*cking is an exercise not limited to presidential elections, or even to politics at all. Private industry is very good at it, and they can afford to hire high-quality ratf ...

View research reports from Argus and trade ideas from Trading Central to understand future stock performances and find high performing trade ideas.

Jim has worked in the financial services industry for over 25 years and joined Argus in 1993. He is director of research at Argus and a member of the Investment Policy Committee. Jim has been ...